Long-term response to regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A systematic literature review (SLR)

被引：0
|
作者：
Peeters, M. [1 ]
Pan, X. [2 ]
Koufopoulou, M. [3 ]
Arregui, M. [4 ]
Wissinger, E. [5 ]
Ostojic, H. [6 ]
Pisa, F. [7 ]
Kim, R. D. [8 ]
机构：
[1] Univ Hosp Antwerp, Ctr Oncol Res, Edegem, Belgium
[2] Bayer Healthcare Pharmaceut Inc, Real World Evidence Oncol, Whippany, NJ 07981 USA
[3] Cencora, Evidence Generat & Value Commun, London, England
[4] Cencora, Evidence Generat & Value Commun, Hannover, Germany
[5] Cencora, Evidence Generat & Value Commun, Conshohocken, PA USA
[6] Bayer Consumer Care AG, Global Med Affairs, Basel, Switzerland
[7] Bayer AG, Real World Evidence Oncol, Berlin, Germany
[8] H Lee Moffitt Canc Ctr & Res Inst, Gastrointestinal Oncol, Tampa, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64P
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 50 条
  • [21] METASTATIC COLORECTAL CANCER (MCRC) - LITERATURE REVIEW ON QUALITY OF LIFE INSTRUMENTS
    Lebioda, A.
    Krieger, T.
    Kuhn, A.
    VALUE IN HEALTH, 2018, 21 : S81 - S81
  • [22] Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience
    Sforza, V.
    Capasso, A.
    Nappi, A.
    Cardone, C.
    Martini, G.
    Ferrara, M. L.
    Napolitano, S.
    Vitiello, P.
    Vitale, P.
    Zanaletti, N.
    De Vita, F.
    Orditura, M.
    Troiani, T.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SYSTEMATIC LITERATURE REVIEW (SLR) AND FEASIBILITY ASSESSMENT OF CONDUCTING INDIRECT TREATMENT COMPARISON (ITC) ANALYSIS
    Xu, Y.
    Martin, A. L.
    Ross, S.
    Knopf, K. B.
    Strand, L.
    Iqbal, S. U.
    Joulain, F.
    Mosqueda, Jasso J. G.
    Fahrbach, K.
    VALUE IN HEALTH, 2013, 16 (07) : A395 - A396
  • [24] Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)
    Cleton, A.
    Sturm, I.
    Trnkova, Z. Jirakova
    Grevel, J.
    Fiala-Buskies, S.
    Lettieri, J.
    ANNALS OF ONCOLOGY, 2015, 26
  • [25] Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial
    Chang, Jane
    Ngai, Christopher
    Odom, Dawn
    Radder, Christina
    Kappeler, Christian
    Xu, Rui-hua
    Qin, Shukui
    Kim, Tae Won
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study.
    Ducreux, Michel
    Petersen, Lone Norgard
    Ohler, Leopold
    Bergamo, Francesca
    Metges, Jean-Philippe
    de Groot, Jan Willem
    Wang, Chao-Yuan
    Garcia-Paredes, Beatriz
    Dochy, Emmanuelle
    Fiala-Buskies, Sabine
    Cervantes, Andres
    O'Connor, Juan Manuel
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [27] Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
    O'Connor, J. M.
    Ducreux, M.
    Petersen, L. N.
    Oehler, L.
    Bergamo, F.
    Metges, J-P.
    de Groot, J. W.
    Wang, J-Y.
    Garcia Paredes, B.
    Dochy, E.
    Fiala-Buskies, S.
    Cervantes, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study
    Grothey, Axel
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Barone, Carlo
    Adenis, Antoine
    Argiles, Guillem
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Sargent, Daniel J.
    Cihon, Frank
    Wagner, Andrea
    Cupit, Lisa
    Laurent, Dirk
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).
    Khan, Khururn Hayat
    Rata, Mihaela
    Koh, Dow-Mu
    Tunariu, Nina
    Vlachogiannis, George
    Hahne, Jens
    Jamin, Yann
    Collins, David J.
    Chau, Ian
    Rao, Sheela
    Watkins, David J.
    Starling, Naureen
    Kalaitzaki, Eleftheria
    Fotiadis, Nicos
    Begum, Ruwaida
    Temple, Eleanor
    Fassan, Matteo
    Braconi, Chiara
    Cunningham, David
    Valeri, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [30] Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab (Pmab) for metastatic colorectal cancer (mCRC)
    Koehne, C. -H.
    Peeters, M.
    Carrato, A.
    Coriat, R.
    Rivera, F.
    Koukakis, R.
    Demonty, G.
    Geissler, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 124 - +
12345